On Saturday, hundreds of thousands of people (and quite a few dogs) took to the streets of major cities around the world to highlight the immense value of science, while also protesting proposed budget cuts and a move away from evidence-based policy decisions.
Biopharma markets are never dull. The winners win big and the companies that lose are harshly penalized. Now the dust has settled, here's the final tally from Evaluate Pharma's review of biopharma markets in 2016.
When it comes to managing inbound phone calls, underperformance has devastating cost implications.
After its shares plunged nearly 50 percent in October, Alnylam, the double-stranded RNAi company, is trying to resurrect itself with new data at the annual meeting of the American Society of Hematology (ASH).